Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-10-03, Stock:LLY, The news for the past five days is as follows:
2018-09-26: NEWS1: Chugai and Lilly Enter into a License Agreement for Oral GLP-1 Agonist, OWL833.NEWS2: Novartis to Cut Over 2000 Jobs, Focus on Higher Value Drugs.NEWS3: Novartis to Cut Over 2000 Jobs, Focus on Higher Value Drugs.NEWS4: Novartis to Cut Over 2000 Jobs, Focus on Higher Value Drugs.NEWS5: Pfizer’s Revenue and EPS Growth Rate.NEWS6: Glaxo's Tuberculosis Vaccine Positive in Mid-Stage Study.NEWS7: Glaxo's Tuberculosis Vaccine Positive in Mid-Stage Study.NEWS8: JPMorgan Resumes Coverage Of Eli Lilly: 'One Of The Best-Positioned Names In Our Group'.NEWS9: JP Morgan says buy Eli Lilly shares on its pipeline, predicts soaring profitability for drug maker.NEWS10: JP Morgan says buy Eli Lilly shares on its pipeline, predicts soaring profitability for drug maker.NEWS11: Is Eli Lilly and (LLY) Outperforming Other Medical Stocks This Year?.NEWS12: Is Eli Lilly and (LLY) Outperforming Other Medical Stocks This Year?.NEWS13: Glaxo&apos;s Tuberculosis Vaccine Positive in Mid-Stage Study.NEWS14: Analyzing Eli Lilly’s Valuation Trends.NEWS15: Is Eli Lilly and (LLY) Outperforming Other Medical Stocks This Year?.NEWS16: A Look at Eli Lilly’s Elanco Spin-Off.NEWS17: Allergan’s SpotLyte and Lumivive System.NEWS18: See what the IHS Markit Score report has to say about Eli Lilly And Co..NEWS19: Analyzing Perrigo’s Spin-Off of Its Rx Business.NEWS20: A Closer Look at the Allergan–Bonti Deal.
2018-09-27: NEWS1: Lilly's Emgality™ (galcanezumab-gnlm) Receives U.S. FDA Approval for the Preventive Treatment of Migraine in Adults.NEWS2: FDA Approves Lilly's Emgality For Preventive Treatment Of Migraine In Adults.NEWS3: FDA Approves Lilly's Emgality For Preventive Treatment Of Migraine In Adults.NEWS4: MannKind Stock History.NEWS5: MannKind Stock History.NEWS6: U.S. judge dismisses Teva lawsuits against Lilly on migraine drug.NEWS7: Trade of the Day: Eli Lilly (LLY).NEWS8: Trade of the Day: Eli Lilly (LLY).NEWS9: Here's Why Eli Lilly (LLY) is a Great Momentum Stock to Buy.NEWS10: Here's Why Eli Lilly (LLY) is a Great Momentum Stock to Buy.NEWS11: Big Pharma Players on Strong Footing Ahead of Q4: 4 Picks.NEWS12: Big Pharma Players on Strong Footing Ahead of Q4: 4 Picks.NEWS13: Here&apos;s Why Eli Lilly (LLY) is a Great Momentum Stock to Buy.NEWS14: Big Pharma Players on Strong Footing Ahead of Q4: 4 Picks.NEWS15: A Look at Pfizer’s Market Cap and Shareholding Pattern.NEWS16: Trade of the Day: Eli Lilly (LLY).NEWS17: The Daily Biotech Pulse: Hologic Goes Shopping, Johnson & Johnson Snaps Ties With Geron.NEWS18: Assessing Pfizer’s Global Performance.
2018-09-28: NEWS1: Tesla and More Mark End of Quarte; FDA OKs Lilly's Migraine Drug -- ICYMI.NEWS2: Winners and losers for Friday, September 28th.NEWS3: Health Care Sector Update for 09/28/2018: LLY,SPRO,CCXI,ALDX.NEWS4: Health Care Sector Update for 09/28/2018: LLY,SPRO,CCXI,ALDX.NEWS5: Teva Announces First-to-File Launch of Generic Cialis.NEWS6: Sanofi Stock Up 2.8% in September: What Lies Ahead?.NEWS7: A Look at Eli Lilly’s Revenue Growth Rate.NEWS8: Eli Lilly's FDA-Approved Migraine Drug is Welcomed by the 38 Million Sufferers.NEWS9: Top Research Reports for Alphabet, Bank of America & PepsiCo.NEWS10: Top Research Reports for Alphabet, Bank of America & PepsiCo.NEWS11: Eli Lilly (LLY) Gets FDA Nod for Migraine Drug Emgality.NEWS12: Eli Lilly (LLY) Gets FDA Nod for Migraine Drug Emgality.NEWS13: Sanofi Stock: How Much Upside Potential Does Wall Street See?.NEWS14: What’s Eli Lilly’s Valuation as of September 27?.NEWS15: Stocks - Tesla Tumbles in Pre-market; Eli Lilly, BlackBerry Gain.NEWS16: Eli Lilly (LLY) Gets FDA Nod for Migraine Drug Emgality.NEWS17: Eli Lilly’s Stock Performance in September.NEWS18: Lilly Bio-Medicines president on new Emgality migraine dr....NEWS19: Google CEO in DC, Eli Lilly gets green light, Boeing wins big.NEWS20: Top Research Reports for Alphabet, Bank of America & PepsiCo.NEWS21: Comparing Pfizer Stock and Merck and Co. Stock.NEWS22: Google CEO in DC, Eli Lilly gets green light, Boeing wins big.NEWS23: Pharma Stock Roundup: PFE, LLY Get Approval for New Drugs, Novartis to Cut Jobs.NEWS24: Three new drugs will compete fiercely to revolutionize migraine treatment — with identical $6,900 price tags.NEWS25: The Daily Biotech Pulse: FDA Nods For Adamis, Eli Lilly, Pfizer; Spero, Obseva Report Positive Trial Results.NEWS26: Technical Indicators for Pfizer Stock’s Movements.NEWS27: U.S. FDA approves Lilly migraine drug; price same as rivals.NEWS28: Eli Lilly Migraine Drug Approved and Will Be Free to Patients.NEWS29: Eli Lilly Migraine Drug Approved and Will Be Free to Patients.
2018-10-01: NEWS1: Do You Know Who Else Invests In Eli Lilly and Company (NYSE:LLY)?.NEWS2: Mylan Stock Declined ~12% Year-to-Date: Could It Recover Soon?.NEWS3: How GlaxoSmithKline’s Pharmaceutical Business Performed.NEWS4: Eli Lilly’s Earnings Quality and Dividend Performance.NEWS5: The Zacks Analyst Blog Highlights: Alphabet, Bank of America, PepsiCo, Eli Lilly and Intuitive Surgical.NEWS6: The Zacks Analyst Blog Highlights: Alphabet, Bank of America, PepsiCo, Eli Lilly and Intuitive Surgical.NEWS7: Eli Lilly’s Market Cap and Shareholding Pattern.NEWS8: Comparing Pfizer Stock and Eli Lilly Stock.NEWS9: See what the IHS Markit Score report has to say about Eli Lilly And Co..NEWS10: The Zacks Analyst Blog Highlights: Alphabet, Bank of America, PepsiCo, Eli Lilly and Intuitive Surgical.NEWS11: Assessing Eli Lilly’s Latest Performance by Segment.
2018-10-02: NEWS1: Health Care Sector Update for 10/02/2018: MMSI,JNJ,LLY.NEWS2: Health Care Sector Update for 10/02/2018: MMSI,JNJ,LLY.NEWS3: Examining the Performances of Eli Lilly’s Oncology Products.NEWS4: Health Care Sector Update for 10/02/2018: JNJ,LLY.NEWS5: Health Care Sector Update for 10/02/2018: JNJ,LLY.NEWS6: How Eli Lilly’s Cardiovascular Products Have Been Faring.NEWS7: Migraine sufferers: Help is on the way from 3 new drugs, but they’ll cost $6,900 a year.NEWS8: See what the IHS Markit Score report has to say about Eli Lilly And Co..NEWS9: Stocks making the biggest move premarket: PEP, AMZN, SFIX, CVX & more.NEWS10: Does Mylan’s Low Valuation Provide a ‘Buy’ Opportunity?.NEWS11: A Closer Look at Eli Lilly’s Human Pharmaceutical Business.NEWS12: Eli Lilly's diabetes treatment meets main goal in two late-stage studies.NEWS13: Results from Two Phase 3 Studies Show Lilly's Ultra Rapid Lispro (URLi) Met Primary Efficacy Endpoint in People with Type 1 and Type 2 Diabetes.NEWS14: Eli Lilly: Phase 3 Studies Show URLi Meets Primary Efficacy Endpoint.NEWS15: Eli Lilly: Phase 3 Studies Show URLi Meets Primary Efficacy Endpoint.

Answer: Rise